# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-272383
Filing Date
2025-11-07
Accepted
2025-11-07 16:16:01
Documents
88
Period of Report
2025-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | gyre-20250930.htm iXBRL | 10-Q | 4065169
2 | EX-31.1 | gyre-ex31_1.htm | EX-31.1 | 19958
3 | EX-31.2 | gyre-ex31_2.htm | EX-31.2 | 19844
4 | EX-32.1 | gyre-ex32_1.htm | EX-32.1 | 15836
5 | EX-32.2 | gyre-ex32_2.htm | EX-32.2 | 15705
| Complete submission text file | 0001193125-25-272383.txt |  | 16489586

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | gyre-20250930.xsd | EX-101.SCH | 1698358
91 | EXTRACTED XBRL INSTANCE DOCUMENT | gyre-20250930_htm.xml | XML | 3901861

Mailing Address 12770 HIGH BLUFF DRIVE SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE SUITE 150 SAN DIEGO CA 92130 (858) 567-7770
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51173 | Film No.: 251462862
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)